Strobel C T, Byrne W J, Ament M E
Gastroenterology. 1979 Aug;77(2):272-9.
Seventeen pediatric patients, ages 9.25--20.5 yr, were placed on a program of home parenteral nutrition (HPN) for severe, symptomatic Crohn's disease. Prior therapy with sulfasalazine in 14, adrenocorticosteroids in 12, inpatient total parenteral nutrition in 7, and/or surgical resections in 6 failed to suppress disease activity. Remission was attained in 12 of the 17 after one course of HPN alone. Four patients had surgical procedures and 1 required steroids in addition to HPN. Remissions have been maintained in 4 of those 12 for a mean duration of 315 days after discontinuation of HPN. Of the 8 who relapsed after a mean duration of 68 days, second courses of HPN were undertaken in 7 and third courses in 2. All 17 had a marked improvement in disease symptoms while receiving HPN in addition to gaining weight sufficient to place them at a higher percentile on standard growth charts. Ten patients demonstrated "catch-up" growth and 4 others increased their height appropriately. A chromium 51-labeled albumin stool collection of greater than 1% in 5 of 7 patients at the completion of a HPN course correlated with relapse within 4 mo. Serial radiographic contrast studies and erythrocyte sedimentation rates were not predictive of prolonged remissions. Home parenteral nutrition complications were minimal, with only one episode of sepsis per 5.8 catheter experience years. It is concluded that HPN is a safe and effective means of inducing remissions and providing optimal nutritional support in pediatric patients with severe Crohn's disease. Patients with less than adequate response to standard medical management should be considered candidates for this therapeutic modality.
17名年龄在9.25至20.5岁之间的儿科患者因严重的症状性克罗恩病接受了家庭肠外营养(HPN)治疗。14名患者之前接受过柳氮磺胺吡啶治疗,12名接受过肾上腺皮质类固醇治疗,7名接受过住院全肠外营养治疗,6名接受过手术切除,但这些治疗均未能抑制疾病活动。仅经过一个疗程的HPN治疗后,17名患者中有12名实现了缓解。4名患者接受了手术,1名患者除HPN外还需要使用类固醇。在停止HPN治疗后,这12名患者中有4名的缓解状态持续了平均315天。在平均68天的缓解期后复发的8名患者中,7名接受了第二个疗程的HPN治疗,2名接受了第三个疗程的治疗。所有17名患者在接受HPN治疗期间疾病症状均有明显改善,同时体重增加,足以使他们在标准生长图表上处于更高的百分位。10名患者出现“追赶性”生长,另外4名患者身高也适当增加。在一个HPN疗程结束时,7名患者中有5名的51铬标记白蛋白粪便收集率大于1%,这与4个月内复发相关。连续的放射造影研究和红细胞沉降率并不能预测长期缓解情况。HPN的并发症极少,每5.8个导管使用年仅有1次败血症发作。结论是,HPN是诱导缓解并为患有严重克罗恩病的儿科患者提供最佳营养支持的安全有效方法。对标准药物治疗反应欠佳的患者应考虑采用这种治疗方式。